RTP Mobile Logo
Select Publications

Abida W et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38(32):3763-72. Abstract

Armstrong AJ et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37(32):2974-86. Abstract

Chi KN et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13-24. Abstract

de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091-102. Abstract

Fizazi K et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383:1040-9. Abstract

Higano CS et al. Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. ASCO 2020;Abstract 5542.

Hoffman S et al. TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). ASCO 2020;Abstract 5500.

Hussain M et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020;383(24):2345-57. Abstract

James N et al. Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). ESMO 2020;Abstract 611O.

Mateo J et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:162-74. Abstract

Shore N et al. HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer. ASCO 2020;Abstract 5602.

Shore ND et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020;382(23):2187-96. Abstract

Smith MR et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79(1):150-8. Abstract

Sternberg CN et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020;382(23):2197-206. Abstract

Tombal B et al. CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide. ASCO 2020;Abstract 5569.